Health officials have announced that three pupils at schools in Dorset have been diagnosed with Meningitis B, a potentially fatal strain of the disease. The cases occurred between March 20 and April 15, just weeks after a significant outbreak in Kent. The UK Health Security Agency (UKHSA) has initiated a widespread public health response, offering antibiotics and vaccines to schoolchildren in years 7 to 13 across the Weymouth, Portland, and Chickerell areas of Dorset.

Two of the diagnosed pupils were known to be in contact at Budmouth Academy, a large secondary school in Weymouth. The third pupil attended Wey Valley Academy in Dorset and is believed to be an unconnected case. Fortunately, all three pupils have received treatment and are reported to be 'recovering well.' As a precautionary measure, close contacts of the affected individuals have already been provided with antibiotics.

This cluster of cases follows a recent meningitis outbreak in Kent, which tragically resulted in the deaths of 18-year-old Juliette Kenny and an unnamed 21-year-old, and led to the hospitalization of 19 others. While experts emphasize that the current Dorset outbreak is 'not on the same scale' as the one in Kent, they caution that the infection can spread more easily in social settings among young people. Dr. Beth Smout, deputy director of the UKHSA, acknowledged the potential for further cases linked to these latest incidents in Weymouth and stressed that the expanded offer of antibiotics and vaccination is an 'additional precaution' guided by national guidelines to mitigate infection spread.

The UKHSA has confirmed that the MenB vaccine will be administered in stages, commencing with Budmouth Academy and Wey Valley schools. Students and staff in neighbouring schools, along with other at-risk children outside the initial three affected institutions, will be invited for vaccination after the initial rollout. Dorset Council has expressed concern that the outbreak suggests the 'strain of MenB bacteria is transmitting more widely among young people in Weymouth.'

Meningitis Now has labeled the new cases 'concerning' and commended the UKHSA's swift action in identifying close contacts and providing precautionary antibiotics and MenB vaccinations. The charity underscored the importance of rapid public health intervention in reducing the risk of further cases and encouraged young people to remain vigilant. Health Secretary Wes Streeting has, in the wake of the Kent outbreak, requested the Joint Committee of Vaccination and Immunisation (JCVI) to re-evaluate the evidence regarding a broader rollout of MenB vaccines.

It is crucial for the public to be aware of the symptoms of meningitis, which include fever, headache, drowsiness, shivering, vomiting, and cold hands and feet. In cases of septicaemia, a rash that does not fade when pressed against a glass may also appear. These symptoms can overlap with common viral infections, leading to dangerous delays in diagnosis during the critical initial hours. The UKHSA, through Dr. Sherine Thomas, an infectious diseases consultant, reiterated the importance of public awareness of invasive meningococcal disease symptoms and urged immediate medical attention if they or someone they know develops them. While the risk to the wider population remains low, vigilance and prompt action are paramount. Notably, while the Kent outbreak was attributed to a new variant with significant mutations, the MenB cases in Weymouth are of the same sub-strain type but a different sub-strain to the one recently detected in Kent.